0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Parenteral Formula Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-6K17248
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Parenteral Formula Market Research Report 2024
BUY CHAPTERS

Global Parenteral Formula Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-6K17248
Report
November 2025
Pages:160
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Parenteral Formula Market

The global Parenteral Formula market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Parenteral formulas are specialized liquid formulations administered intravenously to provide essential nutrients and fluids to individuals who are unable to obtain adequate nutrition through oral or enteral routes. Parenteral formulas are typically prescribed for patients with severe gastrointestinal disorders, malabsorption syndromes, or other medical conditions that impair their ability to absorb nutrients from food.
From a downstream perspective, Hospital Pharmacies accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Parenteral Formula leading manufacturers including Baxter International lnc., B.Braun Melsungen AG, Fresenius Kabi AG, Hospira, Inc., Sichuan Kelun Pharmaceutical Co.,Ltd., Otsuka Pharmaceutical Co.,Ltd., Grifols, S.A., Aculife Healthcare Private Limited, Vifor Pharma Group, Terumo Corporation, etc., dominate supply; the top five capture approximately % of global revenue, with Baxter International lnc. leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Parenteral Formula market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Parenteral Formula Market Report

Report Metric Details
Report Name Parenteral Formula Market
Segment by Type
  • Carbohydrates
  • Amino Acids
  • Lipids
  • Electrolytes
  • Vitamins and Minerals
  • Specialty Formulas
Segment by Application
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Baxter International lnc., B.Braun Melsungen AG, Fresenius Kabi AG, Hospira, Inc., Sichuan Kelun Pharmaceutical Co.,Ltd., Otsuka Pharmaceutical Co.,Ltd., Grifols, S.A., Aculife Healthcare Private Limited, Vifor Pharma Group, Terumo Corporation, Nutricia
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Parenteral Formula study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Parenteral Formula Market report?

Ans: The main players in the Parenteral Formula Market are Baxter International lnc., B.Braun Melsungen AG, Fresenius Kabi AG, Hospira, Inc., Sichuan Kelun Pharmaceutical Co.,Ltd., Otsuka Pharmaceutical Co.,Ltd., Grifols, S.A., Aculife Healthcare Private Limited, Vifor Pharma Group, Terumo Corporation, Nutricia

What are the Application segmentation covered in the Parenteral Formula Market report?

Ans: The Applications covered in the Parenteral Formula Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Parenteral Formula Market report?

Ans: The Types covered in the Parenteral Formula Market report are Carbohydrates, Amino Acids, Lipids, Electrolytes, Vitamins and Minerals, Specialty Formulas

1 Study Coverage
1.1 Introduction to Parenteral Formula: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Parenteral Formula Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Carbohydrates
1.2.3 Amino Acids
1.2.4 Lipids
1.2.5 Electrolytes
1.2.6 Vitamins and Minerals
1.2.7 Specialty Formulas
1.3 Market Segmentation by Application
1.3.1 Global Parenteral Formula Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Parenteral Formula Revenue Estimates and Forecasts 2020-2031
2.2 Global Parenteral Formula Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Parenteral Formula Sales Estimates and Forecasts 2020-2031
2.4 Global Parenteral Formula Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Parenteral Formula Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Parenteral Formula Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Carbohydrates Market Size by Manufacturers
3.5.2 Amino Acids Market Size by Manufacturers
3.5.3 Lipids Market Size by Manufacturers
3.5.4 Electrolytes Market Size by Manufacturers
3.5.5 Vitamins and Minerals Market Size by Manufacturers
3.5.6 Specialty Formulas Market Size by Manufacturers
3.6 Global Parenteral Formula Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Parenteral Formula Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Parenteral Formula Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Parenteral Formula Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Parenteral Formula Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Parenteral Formula Sales and Revenue by Type (2020-2031)
6.4 North America Parenteral Formula Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Parenteral Formula Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Parenteral Formula Sales and Revenue by Type (2020-2031)
7.4 Europe Parenteral Formula Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Parenteral Formula Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Parenteral Formula Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Parenteral Formula Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Parenteral Formula Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Parenteral Formula Sales and Revenue by Type (2020-2031)
9.4 Central and South America Parenteral Formula Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Parenteral Formula Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Parenteral Formula Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Parenteral Formula Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Parenteral Formula Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Baxter International lnc.
11.1.1 Baxter International lnc. Corporation Information
11.1.2 Baxter International lnc. Business Overview
11.1.3 Baxter International lnc. Parenteral Formula Product Models, Descriptions and Specifications
11.1.4 Baxter International lnc. Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Baxter International lnc. Parenteral Formula Sales by Product in 2024
11.1.6 Baxter International lnc. Parenteral Formula Sales by Application in 2024
11.1.7 Baxter International lnc. Parenteral Formula Sales by Geographic Area in 2024
11.1.8 Baxter International lnc. Parenteral Formula SWOT Analysis
11.1.9 Baxter International lnc. Recent Developments
11.2 B.Braun Melsungen AG
11.2.1 B.Braun Melsungen AG Corporation Information
11.2.2 B.Braun Melsungen AG Business Overview
11.2.3 B.Braun Melsungen AG Parenteral Formula Product Models, Descriptions and Specifications
11.2.4 B.Braun Melsungen AG Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 B.Braun Melsungen AG Parenteral Formula Sales by Product in 2024
11.2.6 B.Braun Melsungen AG Parenteral Formula Sales by Application in 2024
11.2.7 B.Braun Melsungen AG Parenteral Formula Sales by Geographic Area in 2024
11.2.8 B.Braun Melsungen AG Parenteral Formula SWOT Analysis
11.2.9 B.Braun Melsungen AG Recent Developments
11.3 Fresenius Kabi AG
11.3.1 Fresenius Kabi AG Corporation Information
11.3.2 Fresenius Kabi AG Business Overview
11.3.3 Fresenius Kabi AG Parenteral Formula Product Models, Descriptions and Specifications
11.3.4 Fresenius Kabi AG Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Fresenius Kabi AG Parenteral Formula Sales by Product in 2024
11.3.6 Fresenius Kabi AG Parenteral Formula Sales by Application in 2024
11.3.7 Fresenius Kabi AG Parenteral Formula Sales by Geographic Area in 2024
11.3.8 Fresenius Kabi AG Parenteral Formula SWOT Analysis
11.3.9 Fresenius Kabi AG Recent Developments
11.4 Hospira, Inc.
11.4.1 Hospira, Inc. Corporation Information
11.4.2 Hospira, Inc. Business Overview
11.4.3 Hospira, Inc. Parenteral Formula Product Models, Descriptions and Specifications
11.4.4 Hospira, Inc. Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Hospira, Inc. Parenteral Formula Sales by Product in 2024
11.4.6 Hospira, Inc. Parenteral Formula Sales by Application in 2024
11.4.7 Hospira, Inc. Parenteral Formula Sales by Geographic Area in 2024
11.4.8 Hospira, Inc. Parenteral Formula SWOT Analysis
11.4.9 Hospira, Inc. Recent Developments
11.5 Sichuan Kelun Pharmaceutical Co.,Ltd.
11.5.1 Sichuan Kelun Pharmaceutical Co.,Ltd. Corporation Information
11.5.2 Sichuan Kelun Pharmaceutical Co.,Ltd. Business Overview
11.5.3 Sichuan Kelun Pharmaceutical Co.,Ltd. Parenteral Formula Product Models, Descriptions and Specifications
11.5.4 Sichuan Kelun Pharmaceutical Co.,Ltd. Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Sichuan Kelun Pharmaceutical Co.,Ltd. Parenteral Formula Sales by Product in 2024
11.5.6 Sichuan Kelun Pharmaceutical Co.,Ltd. Parenteral Formula Sales by Application in 2024
11.5.7 Sichuan Kelun Pharmaceutical Co.,Ltd. Parenteral Formula Sales by Geographic Area in 2024
11.5.8 Sichuan Kelun Pharmaceutical Co.,Ltd. Parenteral Formula SWOT Analysis
11.5.9 Sichuan Kelun Pharmaceutical Co.,Ltd. Recent Developments
11.6 Otsuka Pharmaceutical Co.,Ltd.
11.6.1 Otsuka Pharmaceutical Co.,Ltd. Corporation Information
11.6.2 Otsuka Pharmaceutical Co.,Ltd. Business Overview
11.6.3 Otsuka Pharmaceutical Co.,Ltd. Parenteral Formula Product Models, Descriptions and Specifications
11.6.4 Otsuka Pharmaceutical Co.,Ltd. Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Otsuka Pharmaceutical Co.,Ltd. Recent Developments
11.7 Grifols, S.A.
11.7.1 Grifols, S.A. Corporation Information
11.7.2 Grifols, S.A. Business Overview
11.7.3 Grifols, S.A. Parenteral Formula Product Models, Descriptions and Specifications
11.7.4 Grifols, S.A. Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Grifols, S.A. Recent Developments
11.8 Aculife Healthcare Private Limited
11.8.1 Aculife Healthcare Private Limited Corporation Information
11.8.2 Aculife Healthcare Private Limited Business Overview
11.8.3 Aculife Healthcare Private Limited Parenteral Formula Product Models, Descriptions and Specifications
11.8.4 Aculife Healthcare Private Limited Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Aculife Healthcare Private Limited Recent Developments
11.9 Vifor Pharma Group
11.9.1 Vifor Pharma Group Corporation Information
11.9.2 Vifor Pharma Group Business Overview
11.9.3 Vifor Pharma Group Parenteral Formula Product Models, Descriptions and Specifications
11.9.4 Vifor Pharma Group Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Vifor Pharma Group Recent Developments
11.10 Terumo Corporation
11.10.1 Terumo Corporation Corporation Information
11.10.2 Terumo Corporation Business Overview
11.10.3 Terumo Corporation Parenteral Formula Product Models, Descriptions and Specifications
11.10.4 Terumo Corporation Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Terumo Corporation Recent Developments
11.11 Nutricia
11.11.1 Nutricia Corporation Information
11.11.2 Nutricia Business Overview
11.11.3 Nutricia Parenteral Formula Product Models, Descriptions and Specifications
11.11.4 Nutricia Parenteral Formula Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Nutricia Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Parenteral Formula Industry Chain
12.2 Parenteral Formula Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Parenteral Formula Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Parenteral Formula Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Parenteral Formula Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Parenteral Formula Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global Parenteral Formula Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Parenteral Formula Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Parenteral Formula Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Parenteral Formula Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Parenteral Formula Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Parenteral Formula Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Parenteral Formula Sales by Region (2020-2025) & (K Units)
 Table 8. Global Parenteral Formula Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Parenteral Formula Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Parenteral Formula Sales Share by Manufacturers (2020-2025)
 Table 12. Global Parenteral Formula Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Parenteral Formula Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Parenteral Formula by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parenteral Formula as of 2024)
 Table 16. Global Parenteral Formula Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Parenteral Formula Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Parenteral Formula Manufacturing Base and Headquarters
 Table 19. Global Parenteral Formula Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Parenteral Formula Sales by Type (2020-2025) & (K Units)
 Table 23. Global Parenteral Formula Sales by Type (2026-2031) & (K Units)
 Table 24. Global Parenteral Formula Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Parenteral Formula Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Parenteral Formula ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Parenteral Formula Sales by Application (2020-2025) & (K Units)
 Table 29. Global Parenteral Formula Sales by Application (2026-2031) & (K Units)
 Table 30. Parenteral Formula High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Parenteral Formula Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Parenteral Formula Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Parenteral Formula ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Parenteral Formula Growth Accelerators and Market Barriers
 Table 37. North America Parenteral Formula Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Parenteral Formula Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Parenteral Formula Growth Accelerators and Market Barriers
 Table 40. Europe Parenteral Formula Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Parenteral Formula Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Parenteral Formula Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Parenteral Formula Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Parenteral Formula Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Parenteral Formula Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Parenteral Formula Investment Opportunities and Key Challenges
 Table 47. Central and South America Parenteral Formula Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Parenteral Formula Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Parenteral Formula Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Baxter International lnc. Corporation Information
 Table 51. Baxter International lnc. Description and Major Businesses
 Table 52. Baxter International lnc. Product Models, Descriptions and Specifications
 Table 53. Baxter International lnc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Baxter International lnc. Sales Value Proportion by Product in 2024
 Table 55. Baxter International lnc. Sales Value Proportion by Application in 2024
 Table 56. Baxter International lnc. Sales Value Proportion by Geographic Area in 2024
 Table 57. Baxter International lnc. Parenteral Formula SWOT Analysis
 Table 58. Baxter International lnc. Recent Developments
 Table 59. B.Braun Melsungen AG Corporation Information
 Table 60. B.Braun Melsungen AG Description and Major Businesses
 Table 61. B.Braun Melsungen AG Product Models, Descriptions and Specifications
 Table 62. B.Braun Melsungen AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. B.Braun Melsungen AG Sales Value Proportion by Product in 2024
 Table 64. B.Braun Melsungen AG Sales Value Proportion by Application in 2024
 Table 65. B.Braun Melsungen AG Sales Value Proportion by Geographic Area in 2024
 Table 66. B.Braun Melsungen AG Parenteral Formula SWOT Analysis
 Table 67. B.Braun Melsungen AG Recent Developments
 Table 68. Fresenius Kabi AG Corporation Information
 Table 69. Fresenius Kabi AG Description and Major Businesses
 Table 70. Fresenius Kabi AG Product Models, Descriptions and Specifications
 Table 71. Fresenius Kabi AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Fresenius Kabi AG Sales Value Proportion by Product in 2024
 Table 73. Fresenius Kabi AG Sales Value Proportion by Application in 2024
 Table 74. Fresenius Kabi AG Sales Value Proportion by Geographic Area in 2024
 Table 75. Fresenius Kabi AG Parenteral Formula SWOT Analysis
 Table 76. Fresenius Kabi AG Recent Developments
 Table 77. Hospira, Inc. Corporation Information
 Table 78. Hospira, Inc. Description and Major Businesses
 Table 79. Hospira, Inc. Product Models, Descriptions and Specifications
 Table 80. Hospira, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Hospira, Inc. Sales Value Proportion by Product in 2024
 Table 82. Hospira, Inc. Sales Value Proportion by Application in 2024
 Table 83. Hospira, Inc. Sales Value Proportion by Geographic Area in 2024
 Table 84. Hospira, Inc. Parenteral Formula SWOT Analysis
 Table 85. Hospira, Inc. Recent Developments
 Table 86. Sichuan Kelun Pharmaceutical Co.,Ltd. Corporation Information
 Table 87. Sichuan Kelun Pharmaceutical Co.,Ltd. Description and Major Businesses
 Table 88. Sichuan Kelun Pharmaceutical Co.,Ltd. Product Models, Descriptions and Specifications
 Table 89. Sichuan Kelun Pharmaceutical Co.,Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Sichuan Kelun Pharmaceutical Co.,Ltd. Sales Value Proportion by Product in 2024
 Table 91. Sichuan Kelun Pharmaceutical Co.,Ltd. Sales Value Proportion by Application in 2024
 Table 92. Sichuan Kelun Pharmaceutical Co.,Ltd. Sales Value Proportion by Geographic Area in 2024
 Table 93. Sichuan Kelun Pharmaceutical Co.,Ltd. Parenteral Formula SWOT Analysis
 Table 94. Sichuan Kelun Pharmaceutical Co.,Ltd. Recent Developments
 Table 95. Otsuka Pharmaceutical Co.,Ltd. Corporation Information
 Table 96. Otsuka Pharmaceutical Co.,Ltd. Description and Major Businesses
 Table 97. Otsuka Pharmaceutical Co.,Ltd. Product Models, Descriptions and Specifications
 Table 98. Otsuka Pharmaceutical Co.,Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Otsuka Pharmaceutical Co.,Ltd. Recent Developments
 Table 100. Grifols, S.A. Corporation Information
 Table 101. Grifols, S.A. Description and Major Businesses
 Table 102. Grifols, S.A. Product Models, Descriptions and Specifications
 Table 103. Grifols, S.A. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Grifols, S.A. Recent Developments
 Table 105. Aculife Healthcare Private Limited Corporation Information
 Table 106. Aculife Healthcare Private Limited Description and Major Businesses
 Table 107. Aculife Healthcare Private Limited Product Models, Descriptions and Specifications
 Table 108. Aculife Healthcare Private Limited Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Aculife Healthcare Private Limited Recent Developments
 Table 110. Vifor Pharma Group Corporation Information
 Table 111. Vifor Pharma Group Description and Major Businesses
 Table 112. Vifor Pharma Group Product Models, Descriptions and Specifications
 Table 113. Vifor Pharma Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Vifor Pharma Group Recent Developments
 Table 115. Terumo Corporation Corporation Information
 Table 116. Terumo Corporation Description and Major Businesses
 Table 117. Terumo Corporation Product Models, Descriptions and Specifications
 Table 118. Terumo Corporation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 119. Terumo Corporation Recent Developments
 Table 120. Nutricia Corporation Information
 Table 121. Nutricia Description and Major Businesses
 Table 122. Nutricia Product Models, Descriptions and Specifications
 Table 123. Nutricia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 124. Nutricia Recent Developments
 Table 125. Key Raw Materials Distribution
 Table 126. Raw Materials Key Suppliers
 Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 128. Milestones in Production Technology Evolution
 Table 129. Distributors List
 Table 130. Market Trends and Market Evolution
 Table 131. Market Drivers and Opportunities
 Table 132. Market Challenges, Risks, and Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources


List of Figures
 Figure 1. Parenteral Formula Product Picture
 Figure 2. Global Parenteral Formula Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Carbohydrates Product Picture
 Figure 4. Amino Acids Product Picture
 Figure 5. Lipids Product Picture
 Figure 6. Electrolytes Product Picture
 Figure 7. Vitamins and Minerals Product Picture
 Figure 8. Specialty Formulas Product Picture
 Figure 9. Global Parenteral Formula Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 10. Hospital Pharmacies
 Figure 11. Retail Pharmacies
 Figure 12. Online Pharmacies
 Figure 13. Parenteral Formula Report Years Considered
 Figure 14. Global Parenteral Formula Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 16. Global Parenteral Formula Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 17. Global Parenteral Formula Revenue Market Share by Region (2020-2031)
 Figure 18. Global Parenteral Formula Sales (2020-2031) & (K Units)
 Figure 19. Global Parenteral Formula Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 20. Global Parenteral Formula Sales Market Share by Region (2020-2031)
 Figure 21. Top 5 and Top 10 Manufacturers Parenteral Formula Sales Volume Market Share in 2024
 Figure 22. Global Parenteral Formula Revenue Market Share Ranking (2024)
 Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 24. Carbohydrates Revenue Market Share by Manufacturer in 2024
 Figure 25. Amino Acids Revenue Market Share by Manufacturer in 2024
 Figure 26. Lipids Revenue Market Share by Manufacturer in 2024
 Figure 27. Electrolytes Revenue Market Share by Manufacturer in 2024
 Figure 28. Vitamins and Minerals Revenue Market Share by Manufacturer in 2024
 Figure 29. Specialty Formulas Revenue Market Share by Manufacturer in 2024
 Figure 30. Global Parenteral Formula Sales Market Share by Type (2020-2031)
 Figure 31. Global Parenteral Formula Revenue Market Share by Type (2020-2031)
 Figure 32. Global Parenteral Formula Sales Market Share by Application (2020-2031)
 Figure 33. Global Parenteral Formula Revenue Market Share by Application (2020-2031)
 Figure 34. North America Parenteral Formula Sales YoY (2020-2031) & (K Units)
 Figure 35. North America Parenteral Formula Revenue YoY (2020-2031) & (US$ Million)
 Figure 36. North America Top 5 Manufacturers Parenteral Formula Sales Revenue (US$ Million) in 2024
 Figure 37. North America Parenteral Formula Sales Volume (K Units) by Type (2020- 2031)
 Figure 38. North America Parenteral Formula Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 39. North America Parenteral Formula Sales Volume (K Units) by Application (2020-2031)
 Figure 40. North America Parenteral Formula Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 41. US Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 42. Canada Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 43. Mexico Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 44. Europe Parenteral Formula Sales YoY (2020-2031) & (K Units)
 Figure 45. Europe Parenteral Formula Revenue YoY (2020-2031) & (US$ Million)
 Figure 46. Europe Top 5 Manufacturers Parenteral Formula Sales Revenue (US$ Million) in 2024
 Figure 47. Europe Parenteral Formula Sales Volume (K Units) by Type (2020-2031)
 Figure 48. Europe Parenteral Formula Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 49. Europe Parenteral Formula Sales Volume (K Units) by Application (2020-2031)
 Figure 50. Europe Parenteral Formula Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 51. Germany Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 52. France Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 53. U.K. Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 54. Italy Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 55. Russia Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 56. Asia-Pacific Parenteral Formula Sales YoY (2020-2031) & (K Units)
 Figure 57. Asia-Pacific Parenteral Formula Revenue YoY (2020-2031) & (US$ Million)
 Figure 58. Asia-Pacific Top 8 Manufacturers Parenteral Formula Sales Revenue (US$ Million) in 2024
 Figure 59. Asia-Pacific Parenteral Formula Sales Volume (K Units) by Type (2020- 2031)
 Figure 60. Asia-Pacific Parenteral Formula Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 61. Asia-Pacific Parenteral Formula Sales Volume (K Units) by Application (2020-2031)
 Figure 62. Asia-Pacific Parenteral Formula Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 63. Indonesia Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 64. Japan Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 65. South Korea Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 66. China Taiwan Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 67. India Parenteral Formula Revenue (2020-2031) & (US$ Million)
 Figure 68. Central and South America Parenteral Formula Sales YoY (2020-2031) & (K Units)
 Figure 69. Central and South America Parenteral Formula Revenue YoY (2020-2031) & (US$ Million)
 Figure 70. Central and South America Top 5 Manufacturers Parenteral Formula Sales Revenue (US$ Million) in 2024
 Figure 71. Central and South America Parenteral Formula Sales Volume (K Units) by Type (2021-2031)
 Figure 72. Central and South America Parenteral Formula Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 73. Central and South America Parenteral Formula Sales Volume (K Units) by Application (2020-2031)
 Figure 74. Central and South America Parenteral Formula Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 75. Brazil Parenteral Formula Revenue (2020-2025) & (US$ Million)
 Figure 76. Argentina Parenteral Formula Revenue (2020-2025) & (US$ Million)
 Figure 77. Middle East, and Africa Parenteral Formula Sales YoY (2020-2031) & (K Units)
 Figure 78. Middle East and Africa Parenteral Formula Revenue YoY (2020-2031) & (US$ Million)
 Figure 79. Middle East and Africa Top 5 Manufacturers Parenteral Formula Sales Revenue (US$ Million) in 2024
 Figure 80. Middle East and Africa Parenteral Formula Sales Volume (K Units) by Type (2021-2031)
 Figure 81. South America Parenteral Formula Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 82. Middle East and Africa Parenteral Formula Sales Volume (K Units) by Application (2020-2031)
 Figure 83. Middle East and Africa Parenteral Formula Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 84. GCC Countries Parenteral Formula Revenue (2020-2025) & (US$ Million)
 Figure 85. Turkey Parenteral Formula Revenue (2020-2025) & (US$ Million)
 Figure 86. Egypt Parenteral Formula Revenue (2020-2025) & (US$ Million)
 Figure 87. South Africa Parenteral Formula Revenue (2020-2025) & (US$ Million)
 Figure 88. Parenteral Formula Industry Chain Mapping
 Figure 89. Regional Parenteral Formula Manufacturing Base Distribution (%)
 Figure 90. Global Parenteral Formula Production Market Share by Region (2020-2031)
 Figure 91. Parenteral Formula Production Process
 Figure 92. Regional Parenteral Formula Production Cost Structure
 Figure 93. Channels of Distribution (Direct Vs Distribution)
 Figure 94. Bottom-up and Top-down Approaches for This Report
 Figure 95. Data Triangulation
 Figure 96. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners